Advertisement

Topics

Encouraging Survival Data For Lynparza in Metastatic Breast Cancer

08:18 EDT 16 Apr 2018 | SCRIP

OlympiAD data update backs AZ/Merck & Co.'s PARP inhibitor in metastatic breast cancer, but study not powered to give definitive...

      

Related Stories

 

Original Article: Encouraging Survival Data For Lynparza in Metastatic Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "Encouraging Survival Data For Lynparza in Metastatic Breast Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...